Human intestinal microbiota composition is associated with local and systemic inflammation in obesityOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated how the composition of the human intestinal microbiota relates to intestinal permeability and both local and systemic inflammation in obesity. Researchers profiled fecal microbiota using a phylogenetic microarray and compared this to markers of gut and whole-body inflammation. They also assessed gastroduodenal, small intestinal, and colonic permeability using a multisaccharide test, alongside metabolic markers such as HbA1c, transaminases, and lipids.
Who was studied?
The study population consisted of 28 subjects spanning a wide BMI range of 18.6 to 60.3 kg/m2, covering both nonobese and obese individuals. Based on microbiota composition, these subjects segregated into two clusters: one made up predominantly of obese participants (15 of 19) and another made up exclusively of nonobese participants (9 of 9). This design allowed comparison of inflammatory and permeability measures across microbiota-defined groups rather than by BMI category alone.
What were the most important findings?
Intestinal permeability did not differ between the two microbiota clusters, but the obese-predominant cluster showed reduced bacterial diversity, a decreased Bacteroidetes to Firmicutes ratio, and an increased abundance of potentially proinflammatory Proteobacteria. Fecal calprotectin, a marker of intestinal inflammation, was only detectable in a subset of subjects within the obese microbiota cluster (8 of 19, P = 0.02). Plasma C-reactive protein, a marker of systemic inflammation, was also increased in these subjects, linking microbiota composition to both local and systemic inflammatory signals.
What are the greatest implications of this study?
The findings suggest that a distinct, less diverse microbiota profile enriched in Proteobacteria and depleted in Bacteroidetes relative to Firmicutes is associated with detectable gut and systemic inflammation in some obese individuals, independent of measured intestinal permeability. This points to microbiota composition, rather than barrier leakiness alone, as a candidate driver or marker of the inflammatory state seen in obesity. These results support further work on microbiota-targeted strategies to address obesity-associated inflammation.